<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428606</url>
  </required_header>
  <id_info>
    <org_study_id>20-000879</org_study_id>
    <nct_id>NCT04428606</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effect of Synbiotics in Patients With Pre-diabetes</brief_title>
  <acronym>Rheostat</acronym>
  <official_title>Placebo Controlled Pilot Trial to Determine the Effect of Metabolic Rheostat™ and Butyrate Ultra on Hemoglobin A1C and Blood Glucose Levels in Patients With Pre-diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhaoping Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the effect of Metabolic Rheostat™ and Butyrate Ultra on
      blood glucose levels after a liquid meal challenge in patients with prediabetes. In addition,
      the study also aims to look at the effect of Metabolic Rheostat™ and Butyrate Ultra on
      weight, HgbA1c, fasting glucose, cholesterol, triglycerides, inflammation markers, and
      hormones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded, pilot placebo-controlled trial of two interventions compared to
      placebo to determine the effects individually of Metabolic Rheostat™ and Butyrate Ultra daily
      consumption for 8 weeks on glucose homeostasis in subjects with prediabetes. The entire study
      will last 10 weeks including screen. The study will include 20 subjects with prediabetes
      treated with Metabolic Rheostat™; 20 subjects with prediabetes treated with Butyrate Ultra
      and 20 subjects with prediabetes treated with placebo. Participants will take 6 capsules
      daily, two capsules three times per day 30 minutes prior to each meal for 56 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a double blinded, pilot placebo-controlled trial of two interventions compared to placebo to determine the effects individually of Metabolic Rheostat™ and Butyrate Ultra daily consumption for 8 weeks on glucose homeostasis in subjects with prediabetes. The study will include 20 subjects with prediabetes treated with Metabolic Rheostat™; 20 subjects with prediabetes treated with Butyrate Ultra and 20 subjects with prediabetes treated with placebo. Participants will take 6 capsules daily, two capsules three times per day 30 minutes prior to each meal for 56 days.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose effects of dietary supplement: Metabolic Rheostat vs. Butyrate Ultra</measure>
    <time_frame>2 hours</time_frame>
    <description>Determine the effect of Metabolic Rheostat™ and Butyrate Ultra on blood glucose levels after a liquid meal challenge in patients with pre-diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic impact of Metabolic Rheostat and Butyrate Ultra</measure>
    <time_frame>8 weeks</time_frame>
    <description>Determining the effects of Metabolic Rheostat™ and Butyrate Ultra on gut hormones/incretins (including insulin, C-peptide, glucagon, CCK, GLP-1, GIP, and PYY) using Luminex bead-based technology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Metabolic Rheostat and Butyrate Ultra on food addiction and cravings</measure>
    <time_frame>8 weeks</time_frame>
    <description>Exploratory of Food Addiction (FA) using the Yale Food Addiction Scale (0 symptoms to 11 symptoms). Scale indications are: mild = 2-3 symptoms plus impairment or distress, moderate = 4-5 symptoms plus impairment or distress, severe = 6 or more symptoms plus impairment or distress).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Metabolic Rheostat™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take 6 capsules of Rheostat daily, two capsules three times per day 30 minutes prior to each meal for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Butyrate Ultra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take 6 capsules Butyrate Ultra daily, two capsules three times per day 30 minutes prior to each meal for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take 6 capsules of placebo daily, two capsules three times per day 30 minutes prior to each meal for 56 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Metabolic Rheostat</intervention_name>
    <description>Metabolic Rheostat™ Ingredients: Ginseng extract, Ginseng root extract, berberine chloride, Livaux (gold kiwi powder), MegaSporeBiotic, and MenaquinGold (vitamin K2-7) powder</description>
    <arm_group_label>Metabolic Rheostat™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Butyrate Ultra</intervention_name>
    <description>An anerobic probiotic supplement that contains butyrate-producing Butyricicoccus pullicaecorum 25-3T, vitamin K2, and fenugreek to maintain healthy glucose balance.</description>
    <arm_group_label>Butyrate Ultra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects with pre-diabetes.

          2. Age&gt; 18 years

          3. Ability to understand and the willingness to sign a written informed consent.

          4. Willing and able to comply with trial protocol and follow-up.

        Exclusion Criteria:

          1. Current use of any other investigational agent.

          2. Current use of any agent for treatment of diabetes.

          3. History of adverse effects, intolerance, or allergic reactions attributed to any
             medications.

          4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          5. Abnormal blood analysis for complete blood count (CBC), hepatic and renal injury
             tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gail Thames</last_name>
    <phone>310-825-0453</phone>
    <email>Gthames@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dina Ben-Nissan</last_name>
    <phone>310-206-2582</phone>
    <email>dbennissan@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Center for Human Nutrition, 1000 Veteran Ave.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Zhaoping Li</investigator_full_name>
    <investigator_title>Chief / Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>glucose control</keyword>
  <keyword>microbiome</keyword>
  <keyword>prediabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

